To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Iproniazid (iproniazid phosphate, marketed under the names Marsilid®, Iprozid®, Ipronid®, Rivivol®, Propilniazida®) is a monoamine oxidase inhibitor (MAOI) that was developed as the first anti-depressant. It was originally intended to treat tuberculosis when it was discovered that patients given iproniazid became "inappropriately happy," subsequently with further research iproniazid was marketed specifically for depression in 1958. It was later replaced by less hepatotoxic drugs, particularly isocarboxazid.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Iproniazid". A list of authors is available in Wikipedia.|